



MEMORANDUM

TO: Valued CHIP, STAR & STAR+PLUS Providers

FROM: El Paso Health

DATE: 9/26/2024

RE: Reminder: VDP Changed PDL Status for "Glucocorticoids, Inhaled"
Drug Class Effective Dec. 15, 2023

The drug manufacturer discontinued the brand name Flovent HFA products on Dec. 31, 2023. VDP removed the non-preferred status from the authorized generic (AG) fluticasone HFA and QVAR Redihaler products on the preferred drug list (PDL).

HHSC removed the non-preferred status of the drugs in the table below, effective Dec. 15, 2023:

NDC	Drug Name
66993007896	FLUTICASONE PROP HFA 44 MCG
66993007996	FLUTICASONE PROP HFA 110 MCG
66993008096	FLUTICASONE PROP HFA 220 MCG
59310030240	QVAR REDIHALER 40 MCG
59310030480	QVAR REDIHALER 80 MCG

These changes allowed providers to prescribe the authorized generic (AG) fluticasone HFA and brand name QVAR Redihaler products without requiring a PDL prior authorization and continue access to necessary medication for members.

EPHP9702409



El Paso Health
HEALTH PLANS FOR EL PASOANS. BY EL PASOANS.

MEMORANDUM

The July 2024, the Drug Utilization Review Board reviewed the Glucocorticoids, Inhaled PDL drug class, and fluticasone HFA authorized generic (AG) was recommended as non-preferred. On the Jan. 2025 PDL, fluticasone HFA authorized generic (AG) will no longer be available without a PDL prior authorization. The board recommended QVAR Redihaler, Asmanex HFA, Arnuity Ellipta, and Airduo Respiclick as preferred products. Other preferred products in the Glucocorticoids, Inhaled PDL drug class include Advair Diskus, Advair HFA, Asmanex Twisthaler, budesonide respules, Dulera, Pulmicort Flexhaler, and Symbicort. VDP will implement the July 2024 PDL decisions in Jan. 2025. Refer to the [DUR Board Documents](#) page for the board's PDL decisions and recommendations.

If you have any questions regarding this communication please contact our Provider Relations team at 915-532-3778 or email us at ProviderRelationsDG@elpasohealth.com.